These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12575962)

  • 1. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
    Kaul P; Newby LK; Fu Y; Hasselblad V; Mahaffey KW; Christenson RH; Harrington RA; Ohman EM; Topol EJ; Califf RM; Van de Werf F; Armstrong PW;
    J Am Coll Cardiol; 2003 Feb; 41(3):371-80. PubMed ID: 12575962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
    Newby LK; Ohman EM; Christenson RH; Moliterno DJ; Harrington RA; White HD; Armstrong PW; Van De Werf F; Pfisterer M; Hasselblad V; Califf RM; Topol EJ
    Circulation; 2001 Jun; 103(24):2891-6. PubMed ID: 11413076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
    Hersi A; Fu Y; Wong B; Mahaffey KW; Harrington RA; Califf RM; Van de Werf F; Armstrong PW;
    Eur Heart J; 2003 Mar; 24(6):522-31. PubMed ID: 12643885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective R.OS.A.I.-2 registry.
    Registro Osservazionale Angina Instabile Investigators
    Ital Heart J; 2003 Nov; 4(11):782-90. PubMed ID: 14699708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
    Morrow DA; Cannon CP; Rifai N; Frey MJ; Vicari R; Lakkis N; Robertson DH; Hille DA; DeLucca PT; DiBattiste PM; Demopoulos LA; Weintraub WS; Braunwald E;
    JAMA; 2001 Nov; 286(19):2405-12. PubMed ID: 11712935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk stratification in acute coronary syndrome].
    Goldmann BU; Hamm CW
    Herz; 2001 Apr; 26 Suppl 1():24-9. PubMed ID: 11349623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
    Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
    JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee.
    Moliterno DJ
    Am Heart J; 2000 Apr; 139(4):563-6. PubMed ID: 10740135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction.
    Wong GC; Morrow DA; Murphy S; Kraimer N; Pai R; James D; Robertson DH; Demopoulos LA; DiBattiste P; Cannon CP; Gibson CM
    Circulation; 2002 Jul; 106(2):202-7. PubMed ID: 12105159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes.
    Chew DP; Roffi M; Topol EJ
    Prog Cardiovasc Dis; 2001; 44(3):195-206. PubMed ID: 11727277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of admission cardiac troponin T in patients treated successfully with direct percutaneous interventions for acute ST-segment elevation myocardial infarction.
    Kurowski V; Hartmann F; Killermann DP; Giannitsis E; Wiegand UK; Frey N; Müller-Bardorff M; Richardt G; Katus HA
    Crit Care Med; 2002 Oct; 30(10):2229-35. PubMed ID: 12394949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.
    Giannitsis E; Wallentin L; James SK; Bertilsson M; Siegbahn A; Storey RF; Husted S; Cannon CP; Armstrong PW; Steg PG; Katus HA;
    Eur Heart J Acute Cardiovasc Care; 2017 Sep; 6(6):500-510. PubMed ID: 27044282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
    Januzzi JL; Cannon CP; Theroux P; Boden WE
    Am Heart J; 2003 Nov; 146(5):764-74. PubMed ID: 14597924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.